A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment
Abstract Background The conventional clinical trial design in Alzheimer’s disease (AD) and AD-related disorders (ADRDs) is the parallel-group randomized controlled trial. However, in heterogeneous disorders like AD/ADRDs, this design requires large sample sizes to detect meaningful effects in an “av...
Main Authors: | Libby A. DesRuisseaux, Victoria J. Williams, Alison J. McManus, Anoopum S. Gupta, Becky C. Carlyle, Hamed Azami, Jessica A. Gerber, Anna M. Bolling, Carolyn L. Cook, Rebecca A. Betensky, Steven E. Arnold |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-020-04752-x |
Similar Items
-
Registration of phase 3 crossover trials on ClinicalTrials.gov
by: Lijuan Zeng, et al.
Published: (2020-07-01) -
Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial
by: Yan Press, et al.
Published: (2021-02-01) -
Methylphenidate and Seizures
by: J Gordon Millichap
Published: (1989-10-01) -
Adherence to Ketogenic and Mediterranean Study Diets in a Crossover Trial: The Keto–Med Randomized Trial
by: Matthew J. J. Landry, et al.
Published: (2021-03-01) -
Effects of 16 Weeks of Methylphenidate Treatment on Actigraph-Assessed Sleep Measures in Medication-Naive Children With ADHD
by: Michelle M. Solleveld, et al.
Published: (2020-02-01)